While Amgen (AMGN) Primary Endpoint Was Below Expectations, Secondary Endpoint was Encouraging - Goldman Sachs
Tweet Send to a Friend
Goldman Sachs analyst Terence Flynn weighed in on Amgen (NASDAQ: AMGN) after full data from Repatha (PCSK9) Ph3 cardiovascular outcomes ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
